Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial - Raab, Marc-Steffen; Engelhardt, Monika; Blank, Antje; Goldschmidt, Hartmut; Agis, Hermine; Blau, Igor W.; Einsele, Hermann; Ferstl, Barbara; Schub, Natalie; Röllig, Christoph; Weisel, Katja; Winderlich, Mark; et al. (The lancet. Haematology, 2020)
Gesehen am 15.07.2020